The University of Chicago Header Logo

Connection

Mary Dolan to Polymorphism, Single Nucleotide

Back to Details
This is a "connection" page, showing publications Mary Dolan has written about Polymorphism, Single Nucleotide.
Mary Dolan
Connection Strength
5.777
Polymorphism, Single Nucleotide
  1. Comparison of GWAS results between de novo tinnitus and cancer treatment-related tinnitus suggests distinctive roles for genetic risk factors. Sci Rep. 2024 11 14; 14(1):27952.
    View in: PubMed
    Score: 0.494
  2. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558.
    View in: PubMed
    Score: 0.371
  3. Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 2014 Apr; 10(4):e1004192.
    View in: PubMed
    Score: 0.237
  4. Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet. 2013 Oct 01; 22(19):4007-20.
    View in: PubMed
    Score: 0.223
  5. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013 May 23; 121(21):4366-76.
    View in: PubMed
    Score: 0.220
  6. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer. 2012 Aug 15; 118(16):4063-73.
    View in: PubMed
    Score: 0.202
  7. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
    View in: PubMed
    Score: 0.197
  8. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
    View in: PubMed
    Score: 0.196
  9. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15; 17(16):5490-500.
    View in: PubMed
    Score: 0.195
  10. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A. 2010 May 18; 107(20):9287-92.
    View in: PubMed
    Score: 0.180
  11. Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes. RNA Biol. 2009 Sep-Oct; 6(4):412-25.
    View in: PubMed
    Score: 0.173
  12. Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines. Pharmacogenomics. 2009 Apr; 10(4):549-63.
    View in: PubMed
    Score: 0.167
  13. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009 Mar 05; 113(10):2145-53.
    View in: PubMed
    Score: 0.164
  14. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 01; 68(9):3161-8.
    View in: PubMed
    Score: 0.157
  15. Genetic architecture of transcript-level variation in humans. Am J Hum Genet. 2008 May; 82(5):1101-13.
    View in: PubMed
    Score: 0.157
  16. Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics. 2004 Sep; 14(9):595-605.
    View in: PubMed
    Score: 0.122
  17. Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clin Cancer Res. 2020 06 15; 26(12):2891-2897.
    View in: PubMed
    Score: 0.089
  18. RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants. Genome Biol. 2019 11 28; 20(1):254.
    View in: PubMed
    Score: 0.088
  19. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924.
    View in: PubMed
    Score: 0.085
  20. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. Clin Cancer Res. 2019 07 01; 25(13):4104-4116.
    View in: PubMed
    Score: 0.084
  21. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clin Cancer Res. 2019 02 15; 25(4):1147-1155.
    View in: PubMed
    Score: 0.081
  22. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5757-5768.
    View in: PubMed
    Score: 0.074
  23. Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res. 2017 Aug 01; 23(15):4010-4019.
    View in: PubMed
    Score: 0.073
  24. Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci. 2017 Mar 18; 18(3).
    View in: PubMed
    Score: 0.073
  25. Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res. 2015 Oct 01; 21(19):4337-46.
    View in: PubMed
    Score: 0.064
  26. SCAN database: facilitating integrative analyses of cytosine modification and expression QTL. Database (Oxford). 2015; 2015.
    View in: PubMed
    Score: 0.063
  27. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015 Feb 24; 313(8):815-23.
    View in: PubMed
    Score: 0.063
  28. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52.
    View in: PubMed
    Score: 0.059
  29. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst. 2013 Feb 20; 105(4):302-9.
    View in: PubMed
    Score: 0.054
  30. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9.
    View in: PubMed
    Score: 0.054
  31. Variants affecting exon skipping contribute to complex traits. PLoS Genet. 2012; 8(10):e1002998.
    View in: PubMed
    Score: 0.054
  32. Clinical translation of cell-based pharmacogenomic discovery. Clin Pharmacol Ther. 2012 Oct; 92(4):425-7.
    View in: PubMed
    Score: 0.053
  33. Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet. 2012 Oct 01; 21(19):4348-55.
    View in: PubMed
    Score: 0.052
  34. Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics. 2012 Jul; 22(7):498-507.
    View in: PubMed
    Score: 0.052
  35. Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet. 2012 Feb; 8(2):e1002525.
    View in: PubMed
    Score: 0.051
  36. An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet. 2012 Apr 01; 21(7):1470-80.
    View in: PubMed
    Score: 0.050
  37. Population differences in microRNA expression and biological implications. RNA Biol. 2011 Jul-Aug; 8(4):692-701.
    View in: PubMed
    Score: 0.049
  38. The use of genomic information to optimize cancer chemotherapy. Semin Oncol. 2011 Apr; 38(2):186-95.
    View in: PubMed
    Score: 0.048
  39. Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics. 2010 Apr; 11(4):471-4.
    View in: PubMed
    Score: 0.045
  40. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010 Apr 01; 6(4):e1000888.
    View in: PubMed
    Score: 0.045
  41. Comprehensive survey of SNPs in the Affymetrix exon array using the 1000 Genomes dataset. PLoS One. 2010 Feb 23; 5(2):e9366.
    View in: PubMed
    Score: 0.044
  42. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12.
    View in: PubMed
    Score: 0.044
  43. SCAN: SNP and copy number annotation. Bioinformatics. 2010 Jan 15; 26(2):259-62.
    View in: PubMed
    Score: 0.044
  44. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des. 2009; 15(32):3782-95.
    View in: PubMed
    Score: 0.041
  45. Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet. 2009 Feb; 125(1):81-93.
    View in: PubMed
    Score: 0.041
  46. Population-specific GSTM1 copy number variation. Hum Mol Genet. 2009 Jan 15; 18(2):366-72.
    View in: PubMed
    Score: 0.041
  47. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther. 2008 Sep; 7(9):3038-46.
    View in: PubMed
    Score: 0.040
  48. Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics. 2008 Jun; 18(6):545-9.
    View in: PubMed
    Score: 0.039
  49. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics. 2008 Mar; 18(3):253-62.
    View in: PubMed
    Score: 0.039
  50. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet. 2008 Mar; 82(3):631-40.
    View in: PubMed
    Score: 0.039
  51. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007 Sep; 81(3):427-37.
    View in: PubMed
    Score: 0.037
  52. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 2007 Jun 01; 67(11):5425-33.
    View in: PubMed
    Score: 0.037
  53. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007 Jun 05; 104(23):9758-63.
    View in: PubMed
    Score: 0.037
  54. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45.
    View in: PubMed
    Score: 0.036
  55. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005 Jan 01; 65(1):46-53.
    View in: PubMed
    Score: 0.031
  56. Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. Cancer Res. 2001 Mar 01; 61(5):2307-10.
    View in: PubMed
    Score: 0.024
  57. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
    View in: PubMed
    Score: 0.023
  58. Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity. Pharmacogenomics J. 2019 04; 19(2):178-190.
    View in: PubMed
    Score: 0.020
  59. Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clin Cancer Res. 2017 07 01; 23(13):3325-3333.
    View in: PubMed
    Score: 0.018
  60. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
    View in: PubMed
    Score: 0.017
  61. Linking the genetic architecture of cytosine modifications with human complex traits. Hum Mol Genet. 2014 Nov 15; 23(22):5893-905.
    View in: PubMed
    Score: 0.015
  62. Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. Pharmacogenet Genomics. 2014 May; 24(5):231-7.
    View in: PubMed
    Score: 0.015
  63. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther. 2014 May; 13(5):1334-44.
    View in: PubMed
    Score: 0.015
  64. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep; 14(12):1449-66.
    View in: PubMed
    Score: 0.014
  65. Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):E2343-52.
    View in: PubMed
    Score: 0.013
  66. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011 Oct; 339(1):9-23.
    View in: PubMed
    Score: 0.012
  67. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 2011; 12(5):R46.
    View in: PubMed
    Score: 0.012
  68. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
    View in: PubMed
    Score: 0.012
  69. PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics. 2010 Apr; 20(4):269-73.
    View in: PubMed
    Score: 0.011
  70. Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia. 2007 Oct; 21(10):2128-36.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.